Oragenics Inc
OGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.37M
Close$
$0.08
85.2% downside
Current Fair Value
85.2% downsideOvervalued by 85.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.37 Million |
|---|---|
| Enterprise Value | $-1,495,407.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.56 |
| Beta | 1.24 |
| Outstanding Shares | 4,428,566 |
Return
| Return on Equity | -274.70% |
|---|---|
| Return on Assets | -183.59% |
| Return on Invested Capital | -189.24% |
Valuation & Multiples
| P/E Ratio | -0.15 |
|---|---|
| PEG | -1.3 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.14 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-90.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-72.00
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.43%▼ 0.63% |
|---|---|
| Total Invested | $106,346▼ 37.17% |
| Investors Holding | 20▲ 4.00% |
ESG Score
No data
About Oragenics Inc
7 employeesOragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against infectious disease. The Company is...